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Background: The behaviour of tumour cells depends on factors such as genetics and the tumour
microenvironment. The latter plays a crucial role in normal mammary gland development and also in breast cancer
initiation and progression. Breast cancer tissues tend to be highly desmoplastic and dense matrix as a pre-existing
condition poses one of the highest risk factors for cancer development. However, matrix influence on tumour cell
gene expression and behaviour such as cell migration is not fully elucidated.
Results: We generated high-density (HD) matrices that mimicked tumour collagen content of 20 mg/cm3 that
were ~14-fold stiffer than low-density (LD) matrix of 1 mg/cm3. Live-cell imaging showed breast cancer cells
utilizing cytoplasmic streaming and cell body contractility for migration within HD matrix. Cell migration was
blocked in the presence of both the ROCK inhibitor, Y-27632, and the MMP inhibitor, GM6001, but not by the drugs
individually. This suggests roles for ROCK1 and MMP in cell migration are complicated by compensatory
mechanisms. ROCK1 expression and protein activity, were significantly upregulated in HD matrix but these were
blocked by treatment with a histone deacetylase (HDAC) inhibitor, MS-275. In HD matrix, the inhibition of ROCK1 by
MS-275 was indirect and relied upon protein synthesis and Notch1. Inhibition of Notch1 using pooled siRNA or
DAPT abrogated the inhibition of ROCK1 by MS-275.
Conclusion: Increased matrix density elevates ROCK1 activity, which aids in cell migration via cell contractility. The
upregulation of ROCK1 is epigenetically regulated in an indirect manner involving the repression of Notch1. This is
demonstrated from inhibition of HDACs by MS-275, which caused an upregulation of Notch1 levels leading to
blockade of ROCK1 expression.
Keywords: Breast cancer, High-density matrix, Cancer cell migration, ROCK expression, Histone deacetylase
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Cancer is a complex disease and is strongly influenced
by a number of factors including genetics, epigenetics,
behavioural aspects and the environment. At the cellular
level, these factors impact on cell signalling leading to
uncontrolled proliferation and cell migration with ad-
verse consequences in the formation of tumours and
metastases. The stroma is known to regulate mammary
gland development [1] and under some circumstances,
also promote breast cancer [2]. Stromal contents include* Correspondence: lilian.soon@sydney.edu.au
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reproduction in any medium, provided the orfibroblasts [3,4], immune cells [5,6], adipocytes [7], and
extracellular matrix (ECM), which can regulate the sur-
vival, proliferation and invasion of tumour cells.
Breast cancers have a high stromal content, which is
characterized by activation of fibroblasts (from non-
proliferative fibroblasts to proliferative myofibroblasts),
increased vascularisation, increased deposition of stromal
collagen, and cross-linking and reorientation of ECM
[8,9]. Increased deposition of stromal collagen or “des-
moplasia” is associated with enhanced matrix stiffness.
Desmoplasia can promote the proliferation of normal
and transformed cells and increase cell invasion and
metastasis [10,11]. Furthermore, high mammographically
dense tissue (HMT) as a pre-existing condition poses
one of the highest risk factor for breast cancer deve-
lopment [12]. The predominant component of highLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sisting mostly of collagen [13]. Provenzano et al., [14]
studied mice with a mutation in the α1(I) chain of type 1
collagen that dramatically reduces collagen proteolysis.
Mammary glands of these mice exhibit increased colla-
gen deposition and show signs of hyperplasia such as ir-
regular epithelial boundaries.
Single tumour cell migration in three-dimensional
(3D) matrices can be classified into broad categories
known as amoeboid and mesenchymal migration. Single
tumour cell migration in three-dimensional (3D) matri-
ces can be classified into broad categories known as
amoeboid and mesenchymal migration. Mesenchymal
migration is characterized by elongated spindle-like cell
morphology and requires integrin-mediated matrix-focal
adhesion interactions, cortical F-actin, stress fibres for-
mation, and expression of proteases [15]. Unlike mesen-
chymal migration, amoeboid cells do not require
proteolysis or integrins for migration [16,17]. Amoeboid
migration refers to movement of rounded or ellipsoid
cells, which has no mature focal adhesions and stress fibres
[18]. Cell movement is driven by actin polymerization and
rapid expansion and contraction of the cell body that
allows the cells to squeeze through pores in the ECM [16].
Amoeboid- and mesenchymal-like cells might utilize prote-
olysis for migration depending on the density [19], the
presence of cross-links [20] and the fibrillar or non-fibrillar
nature of the matrices [21]. In the lower spectrum of
matrix densities, amoeboid-like tumour cells exhibit non-
proteolytic migration by Rho-associated coiled-coil forming
kinase (ROCK)-associated contractility or protrusion-led
mechanisms [22,23]. Protrusion-led migration occurs inde-
pendently of integrins and it is driven by protrusions [23].
This can occur in low-density collagen matrices where
contraction-inhibited dendritic cells are able to reach the
same instantaneous velocity peak as control cells mainly
through pushing forces generated by actin polymerisation
during protrusion formation [23].
Increased expression of RhoA or RhoC GTPAses and/
or their ROCK1/2 effectors has been reported in several
metastatic cancers [24], and they play important roles in
tumour progression and invasion [25,26]. These mole-
cules also partake in mechanotransduction of signals in
response to external tensional stimuli [11,27].
This work investigates the role of dense collagen matri-
ces that resemble the matrix densities of mammary
breast cancer tissues in regulating the migration of
tumour cells. MTLn3 rat mammary carcinoma cells were
observed to maneuver between collagen fibrils during
migration into dense matrices utilizing cell contractility.
These cells also have significantly higher ROCK1 activity
levels in high-density (HD) compared to low-density
(LD) matrices, indicating matrix-dependent regulation.
ROCK1 levels and activity were sensitive to HDACinhibition by MS-275, which was abrogated when
Notch1 was blocked. Inhibition of ROCK1 and metallo-
proteases by themselves had no effect on cell migration
indicating alternation of invasion strategies. However, in
the presence of both inhibitors, cell migration was sig-
nificantly blocked.
Results
Preparing in vitro collagen matrices with similar collagen
content and organization to high mammographically-
dense tissues (HMT)
Regions of low or high mammographic density in
prophylactic invasive ductal carcinoma (IDC) tissues
were macrodissected and processed for imaging and
quantitative analyses (Figure 1A). Masson’s Trichrome
staining showed that HMT regions contained mostly
collagen (90%) with isolated clusters of glandular cells
whereas low mammographically-dense tissues (LMT)
consisted mainly of adipose cells with little presence of
collagen (Figure 1B). Collagen concentrations were esti-
mated using picrosirius red to stain collagen and meas-
uring dye uptake at 531 nm absorbance wavelength.
Compared against known standards, the collagen
content in LMT and HMT were measured to be
2.65 ± 1.60 and 19.59 ± 2.91 mg/cm3, respectively
(Figure 1C). High-density (HD) collagen matrix was
prepared by centrifugation to increase collagen concen-
trations and polymerisation using vaporised NH4OH. A
centrifugation time of 60 min was found to be suitable
for preparing HD matrices at 19.16 ± 0.74 mg/cm3,
similar to that for HMT extracts (Figure 1C). The fibril
densities were comparable between HMT tissue and
HD matrix measuring 0.63 ± 0.08 and 0.61 ± 0.07 mm
of fibril/mm2, respectively (Figure 1D). Similarly, in
LMT tissue, the density 0.19 ± 0.09, was similar to that
of LD matrix which measured 0.19 ± 0.07 mm of fibril/
mm2. Pore sizes between tumour tissue and in vitro
matrices are also comparable with HMT and HD pore
sizes measuring 0.025 ± 0.014 and 0.017 ± 0.011, res-
pectively, while those of LMT and LD measure
0.678 ± 0.458 and 0.799 ± 0.695, respectively. The colla-
gen fibril size of the HD matrix was very similar
to HMT tissue, with 62% of the fibrils lying within
125–225 nm for both matrices (data not shown). Fur-
thermore, the matrices resembled the collagen nanos-
tructures and fibrillar networks found in native tissues
[28,29], evident from the presence of ~63 nm D spa-
cings and helical fibril conformations (Figure 1E). To
understand the relationship between cell migration and
matrix density, we compared the properties of low-density
(LD) (1 mg/cm3) and high-density (HD) (20 mg/cm3) col-
lagen matrices. LD matrix contained larger pore spaces
and was less viscoelastic compared to HD matrices
(Figure 2A, B).
A B HMT LMT
200 µm
E
Fibril density
mm of fibril/area 
(mm2)
Pore size
(µm2)
HMT
0.63 
0.08
n = 15
0.025
0.014
n = 100
HD (60 min 
centrifugatio
n)
0.61 
0.07
n = 15
0.017
0.011
n = 100
LMT
0.19
0.09
n = 6
0.678
0.458
n = 30
LD
0.19
0.07
n = 15
0.799
0.695
n = 100
HMT
HD 
D
200 nm
LMT
1 µm
LD
A
bs
o
rb
an
ce
 @
 
53
1 
nm
s
C
0
0.05
0.1
0.15
0.2
0.25
0 10 20 30 40
Collagen (cm3)
Standards LMT
HMT HD (60 min)
LD Linear (Standards)
Figure 1 Preparation of HD collagen gels resembling desmoplastic matrices. A, High-density mammographic tissue (HMT) and low-density
mammographic tissue (LMT) denoted by light and dark radiographic areas respectively, were macrodissected from DCIS mammary tissue and processed.
B, Masson’s Trichrome staining showed abundant collagen fibrils in HMT tissue (blue stain) and mostly adipose cells in LMT tissue. C, In vitro HD matrix
was prepared by centrifugation to concentrate solubilised collagen followed by polymerisation using vaporised NH4OH. HD matrix along with HMT and
LMT samples were stained with picrosirius red and assayed for dye binding at 531 nm wavelength of light. The collagen concentration of HMT (■), LMT
tissues (▲) and HD collagen matrix (●) were extrapolated from standards of known collagen concentrations (♦). After 60 min of centrifugation, HD
collagen measured 19.16 ± 0.74 mg/cm3, which closely correlated with HMT samples of 19.59±2.91 mg/cm3 collagen. D, SEM of HMT tissues and HD
matrix shows that collagen is organized as networks of dense fibrils. Field emission SEM demonstrates that HD collagen consists of small ~30 nm
collagen fibrils that form helical coils of larger 200 nm fibrils (arrows). Collagen D-spacing of ~50–60 nm is visible along the lengths of individual collagen
fibrils and are aligned relative to adjacent coiled fibrils (arrowheads). E, the fibril density and pore sizes of HD (60 min centrifugation) and LD matrices
closely mimicked HMT and LMT counterparts of tumour tissue (n=no. areas sampled). Experiments were repeated three times. Bars indicate standard
deviation from triplicate samples. Scale bars represent 200 μm in B and 1 μm in D.
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expression
Tumour cells of epithelial origins migrate away from the
primary tumour by first breaching the basementmembrane, which has low values of Young’s modulus or
low resistance to elastic deformation. Paszek and
Weaver, 2004 [10], measured this to be 175 ± 37 Pa for
reconstituted basement membrane, which is similar to
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Figure 2 Matrix properties and cell migration. Tumour cells were grown in low-density (LD) matrix of 1 mg/cm3 or high-density (HD) matrix
of 20 mg/cm3. A, The storage modulus (G’, ♦) and the loss modulus (G”, ■) of matrices were graphed against oscillation frequency sweeping from
0.01 to 30 Hz. As the rate of deformation increases, the storage modulus and loss modulus values converge at high deformation rates in LD but
not HD matrix reflecting higher viscoelastic properties in the latter. B, (i), Merged reflection and confocal images of collagen and paxillin-Alexa
568-labelled tumour cells demonstrate larger interfibrillar spaces (*) in LD matrix. (ii) Morphometric indicators show that tumour cells are more
rounded in shape in LD compared to HD matrices (n = 15). (iii), Live-cell confocal microscopy of GFP-actin transfected MTLn3 cells. Cells in LD
matrix appear rounded and form blebs during migration (arrow). In HD matrix, protrusions are extended via ruffling (arrow heads) and terminate
as fine filopodia (inset images). Asterisk indicates the initial cell position. C, Live-cell DIC microscopy shows a typical migration pattern of a
tumour cell through HD matrix. At time 0’, a cell protrusion (P) has breached the fibrous mass. At 5’ 45”, the cell body (B) has partially extended
into the matrix via cytoplasmic propulsion leaving behind the rounded, tall nucleus (N). In later frames, contraction of the cell body facilitated
squeezing of the nucleus past obstructing matrix fibrils, completing the migration cycle by 28’ 45”.
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Our measurements of 1 cm3 collagen matrices also fall
on the low end at <100 Pa. By contrast, HD matrix is ap-
proximately 10-fold stiffer compared to LD matrix. This
suggests that HD matrix recovered more easily from de-
formation while the latter was more susceptible to de-
formation forces (Figure 2A). Therefore, tumour cells
essentially cross from a low collagen content and “malle-
able” milieu of the basement membrane and into highly
dense and rigid collagen matrices (Figure 1). It was alsorecently shown that tumour cells are attracted to regions
of high matrix stiffness, a mechanism known as duro-
taxis [30]. The present model is designed to study how
tumour cells enter HD collagen matrix similar in density
to tumour matrices. Tumour cells are seeded on top of
the HD matrix, which mimics the breaching of tumour
cells from a region of low or negligible stromal density
into highly dense tumour stroma. Seventy-two hours
after seeding, 89% (n = 4 experiments) and 100% (n = 2
experiments) of cells have invaded into LD and HD
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http://www.biomedcentral.com/1471-2121/13/12matrices, respectively. Cell shape was determined from
measurements of Circularity and Aspect Ratio. Circular-
ity ratios approaching 1.0 represent a perfect circle while
Aspect Ratio is the length of the major axis divided by
the minor axis. Cells in LD matrix have larger Circular-
ity values and lower Aspect Ratio values than those in
HD matrix suggesting a rounder cell shape (Figure 2B).
Live-cell confocal microscopy shows that in LD matrix,
the cell appears rounded and during migration, forms
membrane blebs due to contractility of the cortex. In
HD matrix, a very different morphology is apparent
where a large protrusion forms through a series of mem-
brane ruffling and extension events leading to the gener-
ation of fine filopodia distally (Figure 2B). In HD matrix,
the protrusive cell front leads the migration process. The
nucleus, being a tall and rigid structure, required a long
period to move past barricading matrix fibrils. This was
assisted by cytoplasmic streaming and cell contractility
that forced the cell body into the HD matrix (Figure 2C;
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Figure 3 Effect of matrix densities on the expression of invasion- rela
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To investigate whether matrix densities might alter the
expression of invasion-related genes, we performed
quantitative RT-PCR using total RNA from cells migrat-
ing in LD and HD matrices. HD collagen matrix signifi-
cantly increased MT1-MMP, N-WASp, fascin, cortactin
and ROCK1 (Figure 3A). To further investigate how
matrix density might affect ROCK, its expression and
protein activity were quantified. Quantitative PCR results
revealed up to 4 fold higher expression of ROCK1 tran-
script in HD matrix compared to LD matrix. ROCK kin-
ase activity assay was performed using the recombinant
myosin phosphatase targeting subunit 1 (MYPT1) as a
ROCK substrate and anti-phospho-MYPT1 (Thr696) as
the labeling antibody. ROCK inactivates myosin phos-
phates through specific phosphorylation of myosin
phosphatase target subunit1 at Thr696 [MYPT1
(Thr696)]. ROCK activity was also significantly increased
in HD suggesting that MTLn3 cancer cells use more0.0
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Figure 4 Migration of MTLn3 carcinoma cells in HD matrix.
Tumour cells were seeded on matrices for 24 h and treated with
vehicle, the rock inhibitor (RI), Y-27632, and the MMP inhibitor,
GM6001, and allowed to migrate for a further 48 h. The cells were
stained with phalloidin-Alexa488 and imaged by confocal and
reflection microscopies to capture cells and collagen, respectively.
The image stacks were reconstructed in the x-z plane to measure
the depth of cell migration. A, The RI blocked cell migration in
1 mg/cm3 matrix but had no significant effects on cell migration in
higher density matrices of 10 and 20 mg/cm3. B, GM6001
significantly inhibited cells migration at higher concentrations but
had no effect at the lowest concentration of 12.5 μm. C, Cell
migration was significantly inhibited in the presence of both RI
(10 μm) and low concentrations of GM6001 (12.5 μm) compared to
vehicle-treated cells alone. Grey and white boxes show the upper
and lower quartiles, respectively. Upper bars represent the maximum
and lower bars, the minimum distance travelled by cells. Each
experiment was repeated at least twice. 1-way ANOVA followed by
post-hoc Tukey’s test indicating significant difference at * p< 0.05
and ** p< 0.01.
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(Figure 3B).
ROCK inhibition suppressed cell invasion in a context-
dependent manner
The methodology we apply for studying cell migration is
consistent with the above observations. Here, tumour
cells are seeded on top of matrices, and allowed to mi-
grate for several days simulating possible scenarios in vivo
where cells might migrate through matrices with densities
that are from close to zero to as high 20 mg/cm3. Projec-
tions of the x-z plane of confocal microscope indicate that
the tumour cells migrate deeper into the matrix over time.
By 72 h, imaging data confirmed that most cells have be-
come completely submerged into the matrices (not
shown). In order to determine how inhibiting ROCK might
affect the migration of tumour cells, 48 h assays were per-
formed in the presence or absence of the rock inhibitor,
Y-27632. Box and whiskers plot indicate that 50% of
cells lying between the upper and lower quartiles are
migrating distances of between 23 and 40 μm in LD
matrix and 12–18 μm in denser matrices of 10–20 mg/cm3
(Figure 4A). In LD matrix, the presence of the ROCK in-
hibitor reduced the values to 4–6 μm but there were
no significant effects on cell migration in the higher
density matrices (Figure 4A). It is possible that the
tumour cells are adaptable to the inhibitor, switching
to either protrusion- and/or protease-lead migration
modes, masking the effects of Y-27632. To test this,
tumour cells were incubated with Y-27632 as well as
GM6001, the wide spectrum metalloproteinase inhibi-
tor. The MMP inhibitor, GM6001, has been utilized
over a range of concentrations from 10 to 50 μM
[31,32]. At a critical concentration of the GM6001 in-
hibitor (12.5 μM), addition of Y-27632 significantly
blocked cell migration whereas the presence of either
inhibitor alone had no effect (Figure 4B, C).
MS-275 downregulated the protein expression and kinase
activity of ROCK1 in HD matrices
The cellular microenvironment governing cell adhesion
was previously shown to regulate ROCK expression via
epigenetic means [33,34]. We hypothesise that matrix
density might also modulate ROCK in similar ways. To
test this, we used the histone deacetylase inhibitors,
MS-275 and valproic acid (VPA), to investigate whether
histone modification might be responsible for ROCK
activation in HD matrix. There are several naturally oc-
curring and synthetic HDAC inhibitors including
trichostatin A (TSA), suberoylanilide hydroxamic acid
(SAHA), MS-275 and VPA. MS-275 is an orally active,
synthetic HDAC inhibitor that selectively inhibits class 1
HDACs such as HDAC1 and HDAC3 [35]. This benza-
mide derivate has better physicochemical (bio availabilityand stability) properties and less toxicity than trichostatin
(TSA) [36,37]. It has been tested in over 60 human can-
cer cell lines, a variety of human tumour xenograft
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advanced solid tumours or lymphoma [38,39]. Srivastava
et al., 2010 reported that treatment of MS-275 in a breast
cancer mouse model (MDA-MB-468 cells), induced
growth arrest, apoptosis, and inhibited angiogenesis, mi-
gration and metastasis [39]. VPA is an established and
well-tolerated drug for epilepsy. It inhibits class I HDACs
and also shows anti-tumour activity in a variety of
human cancer cell lines including estrogen-sensitive and
estrogen- insensitive breast cancer cell lines [40,41]. It is
less toxic compared to TSA [42] and is in phase II and III
clinical trials for many human cancers [43]. MS-275 and
VPA are selected for this study for their functional simi-
larity and low toxicity. In HD matrix, the expression of
genes associated with invasion such as TGF-β1, ROCK1
and fascin were shown to be significantly downregulated
by MS-275 (Figure 5A). VPA similarly significantly
downregulated ROCK1 at the transcript level (Additional
file 2: Figure S1). In addition, Western blotting demon-
strated that the amount of ROCK1 protein was signifi-
cantly reduced by 60% in the presence of 1 and 3 μM of
MS-275 (Figure 5B). Similarly, a kinase activity assay fol-
lowed by immunoblotting showed that ROCK kinase ac-
tivity was significantly inhibited by treatment with 1 and
3 μM of the MS-275 inhibitor, by 40% and 90%, respect-
ively (Figure 5B).
Blocking protein synthesis abrogated the downregulation
of ROCK1 by MS-275 in HD matrix
MS-275 downregulated ROCK1 expression at the
mRNA and protein levels as well as the activity of
ROCK1. We next asked whether the inhibition of
ROCK1 is a direct effect of MS-275. Cycloheximide
(CHX) is a well-known protein inhibitor that blocks pro-
tein synthesis in vivo and in vitro. CHX interferes the
translocation of amino acids to ribosome by affecting
the ribosomal donor site, thereby blocking translational
initiation and elongation [44]. The use of CHX at
10 μg/ml together with MS-275 abrogated the effects
of MS-275 alone, leading to ROCK1 levels that matched
those of the control untreated sample (Figure 6A).
Therefore, de novo protein synthesis is needed for the
downregulation of ROCK1 by MS-275.
HD matrix reduced Notch1 expression that was
abrogated by MS-275
HD matrix reduced Notch1 expression that was reversed
by MS-275. In human primary keratinocytes, adenoviral
transfection of p53 suppressed the expression of ROCK1
and conversely, downregulation of p53 using siRNA
upregulated the expression of ROCK1 [45]. Furthermore,
knockdown of p53 downregulates Notch1 expression
while p53 activation by ionising radiation or actinomycin
D upregulate Notch1 in human cervical keratinocytes[46]. Yugawa et al., 2007, reported that human Notch1
has several putative p53-resposive sequences and p53
transactivate the Notch1 promoter and regulates its ex-
pression [46]. Notch1 is also regulated independently of
p53, for example, in the p53 deficient cell line, T47D, ac-
tivation of Notch1 occurs through Discoidin domain re-
ceptor tyrosine kinase1 (DDR1) [47]. Furthermore, it is
well studied that HDAC inhibitors, for example VPA,
SBHA and TSA increased Notch1 at transcript and pro-
tein level in many cancers [48,49]. Therefore, it is pos-
sible that Notch1 and/or p53 might be responsible for
the indirect effect of MS-275 on ROCK1 expression. To
test this, we first determined whether the gene expres-
sion of Notch1 and p53 were regulated by matrix dens-
ity, and whether this was in turn affected by MS-275.
HD matrix downregulated the expression of Notch1
(Figure 6B). Furthermore, MS-275 increased Notch1
transcript levels (Figure 6C). Western blot analysis of
Notch1 showed that MS-275 also increased the protein
levels of the intracellular domain of Notch1 (NICD), the
active form of Notch1 (Figure 7A). Unlike Notch 1 ex-
pression, expression of p53 was not altered by matrix
density (Figure 6B) or by MS-275 treatment (Additional
file 3: Figure S2). Therefore, Notch1 is a candidate sup-
pressor of ROCK1 whereby its upregulation by MS-275
might be responsible for indirectly reducing ROCK1
levels. CHX had no effect on Notch1 expression suggest-
ing a direct effect of MS-275 in elevating Notch1 levels
(Figure 6C). Therefore, the expression of Notch-1 might
be downregulated by histone deacetylation, leading to
increased expression of ROCK1 in HD matrix.
In contrast to the effects on Notch1, CHX alone or CHX
and MS-275 treatments caused significant increases in the
expression of p53. There is no precedent for this observa-
tion for p53 but cell cycle genes have been shown to be
upregulated by CHX [50,51]. Furthermore, synergy be-
tween EGF and CHX has led to the upregulation of actin
mRNA transcript [52]. It is likely that these effects are due
to blockade of an inhibitor by CHX so that in some cases,
inhibition of protein synthesis can lead to upregulatory
effects. This reasoning may apply to CHX upregulation of
p53 via either increased stability of p53 mRNA or the tran-
scription rate or both.
MS-275 regulated Notch1 expression leading to the
suppression of ROCK1 in HD matrices
To determine whether the increase in Notch1 expres-
sion by MS-275 might be responsible for the downre-
gulation of ROCK1, we used the Notch1 inhibitor,
DAPT, in combination with MS-275 in quantitative
RT-PCR and kinase assay experiments. The Notch
pathway has a critical cleavage step involving the
γ-secretase complex of four proteins. Enzymatic cleavage
of Notch by γ-secretase complex is essential for the
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(NICD). DAPT is a potent γ-secretase inhibitor that inhi-
bits the formation of NICD and its downstream pathways
[53]. The combination of DAPT and MS-275 abrogated
the down regulation of ROCK1 by MS-275 alone
(Figure 7A). The results were also confirmed using
SMART Pool siRNA to knockdown the expression ofFigure 5 MS-275 reduced the expression of invasive genes including
treat cells 24 h after seeding in HD matrix and the cells were harvested 48
time PCR results showed a significant decrease in the expression of TGF-β1
expression was calculated using ΔΔCt method. B, Western blotting and ac
its activity level following treatment of MS-275. Ratio measurements were o
error from two biological replicates experiments and experiments were rep
indicating significant difference at ** p< 0.01.Notch1 (Figure 7B). Similar data were found when re-
placing MS-275 with VPA. In HD matrix, VPA signifi-
cantly suppressed ROCK1 expression whereas DAPT
increased ROCK1 mRNA level. Treatment with both
VPA and DAPT abrogated the effect of VPA alone, in-
creasing ROCK1 expression to control levels (Additional
file 2: Figure S1).ROCK1 in HD matrices. The HDAC inhibitor, MS-275, was used to
h after treatment for either qPCR or for ROCK activity assay. A, Real-
, fascin and ROCK1 following treatment with MS-275. Relative
tivity assay for ROCK1 demonstrated, the reduction in protein level and
btained following normalisation with α–tubulin. Bars indicate standard
eated three times. 1-way ANOVA followed by post-hoc Tukey’s test
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Figure 6 Reduction of ROCK1 by MS-275 is dependant on protein expression. MTLn3 breast cancer cells were allowed to invade into HD
matrices for 24 h before treatment with 1 μM and 3 μM MS-275, 10 μg/ml of cycloheximide (CHX) and both CHX and MS-275 for a further 24 h
or cells were grown on LD and HD matrix for 72 h to total RNA and protein extraction. A, Real-time PCR results showed that MS-275 alone
decreased ROCK1 expression but this was reversed in the presence of CHX. B, HD significantly suppressed Notch-1 expression at both mRNA and
protein level compared to LD matrix and there was no change in p53 expression. C, MS-275 upregulated Notch1 levels and this was unaffected
by CHX. Bars indicate standard error from two biological samples and experiments were performed two times. 1-way ANOVA followed by post-
hoc Tukey’s test indicating significant difference at either * p< 0.05 or ** p< 0.01.
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Breast tumours have a tendency to be highly desmoplas-
tic with high collagen content. This work explores
ROCK1 activity, regulation and cell contractility function
during cell migration in high-density (HD) matrices.
Live-cell imaging showed that tumour cells navigated
through HD matrices by contraction of the cell body.
Treatment with inhibitors demonstrated a role for
ROCK1 and MMPs in cell migration. There wasincreased expression of invasive genes in HD compared
to LD matrices including ROCK1, whereby both its ex-
pression and activity were significantly upregulated in
denser matrices. This effect of the microenvironment on
ROCK1 was sensitive to treatment with a HDAC inhibi-
tor, MS-275, which upregulated Notch1 that in turn,
suppressed ROCK1. This was shown by downregulation
of Notch1 using siRNA knockdown and DAPT, which
abrogated the inhibition of ROCK1 by MS-275.
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Figure 7 Inhibition of Notch1 abrogates ROCK1 downregulation by MS-275 in HD matrices. A, MTLn3 breast cancer cells invaded into HD
matrix for 24 h and were treated with MS-275, the Notch1-1 inhibitor, DAPT, and combined treatments for 48 h. MS-275 alone decreased ROCK1
transcript level but when used in combination with DAPT, this effect was abrogated. Western blotting for Notch1 demonstrated that increased
expression of Notch-1 intracellular domain (NICD), following MS-275 treatment. Conversely, ROCK activity was reduced by MS-275 and this effect
was lost in cells that were inhibited for Notch-1. B, the knockdown of Notch1 by siRNA demonstrated, there was a reversal of ROCK inhibition by
MS-275 to control levels in cells knockdown for Notch1. The activity of ROCK1 was also increased by 1.3 fold when cells were treated with
Notch1 siRNA and MS-275 together. Ratio measurements were obtained following normalisation with α–tubulin. Bars indicate standard error from
two biological replicates and the experiments were performed thrice for qPCR and twice for Western blot analysis. 1-way ANOVA followed by
post-hoc Tukey’s test indicating significant difference at ** p< 0.01.
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http://www.biomedcentral.com/1471-2121/13/12Dense breast tissue shows increased stromal collagen and
analyses of tumour material indicate that cancerous breast
tissues are stiffer than healthy tissue [8]. Stiffness or resist-
ance to deformation measured from Young’s modulus of
collagen matrices is dependent on the number of fibrillar
cross-links and higher fibre densities [19,54,55]. Stiffer
matrices promote invasion by increasing the numbers of ac-
tive invadopodia [56] and increase cell proliferation by ele-
vating Rho-GTPase activity and cell adhesion [57]. Tumour
cells in turn, remodel the extracellular matrix for example,
by realigning randomly organised collagen fibres into a ra-
dial configuration to help facilitate local invasion [14,15,58].
Tumour cells are also known to use protease to cleave
ECM components and together with other mechanisms to
contract and reorganise the collagen matrix to provide
space required for cell migration [59]. It is conceivable that
matrix reorganisation via pushing of protrusions, contrac-
tion of the cell body and local matrix proteolysis serve to
reduce matrix stiffness and facilitate cell migration. This
study showed that levels of ROCK transcript, protein and
protein activity were significantly upregulated in stiff matri-
ces coincident with the observation of cell body contractil-
ity utilised for migration. Unlike other biological programs
such as proliferation and differentiation where cells are
committed to specific pathways, cells can switch between
regulatory pathways and migration modes for invasion.
Protrusion-, contractility- or protease-led mechanisms are
interchangeably utilised by tumour cells. These are
dependent on environmental conditions and cell proclivities
related to genetic make-up governing polarity, adhesion and
cytoskeletal functions. Variations in these factors lead to a
number of permutations in the migration mode of tumour
cells. For example, blockade of MMPs causes mesenchymal
tumour cells to switch to cell contractility for migration
similar to amoeboid cells in LD matrices [15,22,57,60].
In HD matrix, ROCK inhibition had no effect on mi-
gration even though live DIC microscopy showed evi-
dence of cell contractility. It is possible that in the
absence of ROCK, protease-led migration might com-
pensatory. Indeed, inhibiting both MMPs and ROCK,
cooperatively/synergistically reduced migration levels, al-
beit at the lower end of the GM6001 concentration
(12.5 μm) used. This suggests that at a critical level of
MMPs, ROCK is required for efficient cell migration.
At higher GM6001 concentrations (above 12.5 μm),
addition of ROCK inhibitors has no further effects sug-
gesting that ROCK can no longer compensate for migra-
tion. Here, we are able to glimpse into how tumour cells
are inherently plastic where cells can swap between mi-
gration modes utilising ROCK1 and/or MMPs. Residual
migration (when ROCK1 and proteolysis are inhibited)
suggests that a third pathway is utilised, possibly one
that controls protrusion-led migration. Indeed, we ob-
serve that tumour cells migrate into dense matricesutilising enlarged protrusions that interacts with collagen
fibrils to gain traction (Additional file 1: Movie S1).
Epigenetics have been shown to play a role in regulat-
ing ROCK1 expression as a function of cell adhesion, an
environmental cue [34]. Cells in suspension expressed
more ROCK1 compared with adherent cells and the use
of an HDAC inhibitor further increased the expression
of ROCK1 in suspension cultures. The function of
ROCK1 was to generate cell contractility that blocked
adhesion in the cells in suspension [34]. Here we
explored whether epigenetics might also play a part in
the regulation of ROCK1 when cells experience micro-
environmental differences in matrix stiffness. ROCK1
expression and activity was significantly upregulated in
the highly elastic HD matrix compared to LD matrix.
Blocking HDAC function using MS-275 downregulated
ROCK1 and this could result from either direct or indir-
ect effects of the drug.
HDACs deacetylate histones reducing accessibility of
DNA to the transcription machinery resulting in in-
active chromatin. Furthermore, histone deacetylation
can also lead to methylation-dependent transcriptional
activation [61,62]. There are two possibilities as to how
HDACs might increase ROCK1 transcript in HD
matrix. This might occur directly through HDAC pro-
motion of histone methylation at H3K4Me and activa-
tion of ROCK1 gene transcription (as opposed to
downregulating genes at other methylated sites such as
H3K9Me.). The alternative hypothesis is that in HD
matrix, HDAC suppresses an inhibitor of ROCK1 so
that addition of MS-275 abrogates this suppression,
leading to the downregulation of ROCK1. To test this,
we used cycloheximide (CHX) to block protein transla-
tion and showed that CHX prevented the downregula-
tion of ROCK1 transcript and protein activity in the
presence of MS-275. This suggests that the effect of
MS-275 on ROCK1 is indirect and it is dependent on an-
other protein(s) upregulated by MS-275.
ROCK activity is regulated by Rho GTPase, which frees
the kinase region from the autoinhibitory carboxy-terminal
region of ROCK1 [63] and it is also activated autonomously
from Rho [64]. ROCK phosphorylates substrates that func-
tion in the assembly of actin filaments and in cell contractil-
ity including ezrin-radixin-moesin (ERM) proteins and
MLC [65]. Phosphorylation of the MLC of myosin II acti-
vates myosin ATPase and consequently promotes cell con-
tractility [63]. Furthermore, ROCK also phosphorylates the
myosin-binding subunit (MYPT1) of myosin light–chain
phosphatase (MLCP), a negative regulator of MLC [66],
resulting in enhanced contractility. We show that using
blebbistatin to block myosin II, downstream of ROCK, has
no effect on cell migration (Additional file 4: Figure S3).
Apart from self-regulation at the protein level, ROCK
can be controlled at the transcript level. In keratinocytes,
HD matrix/HDAC
ROCK1-mediated 
Contractility
Notch1
Proteolysis
CELL MIGRATION
Figure 8 Regulatory pathways in the regulation of ROCK1 and
cell migration in HD matrix. HD matrix inhibits Notch1 via HDAC
(s) leading to upregulation of ROCK1 transcript, protein and activity
levels. ROCK1 in turn increases cell contractility and together with
matrix proteolysis, facilitate cell migration into HD matrix.
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hibit ROCK1/2 [45]. Notch is a type I transmembrane re-
ceptor with a key role in cell fate determination and the
differentiation of cells during development. Inhibition of
Notch increases tumour formation by primary human ker-
atinocytes expressing oncogenic Ras, suggesting a tumour
suppressor role for Notch. Blockade of Notch also sup-
pressed differentiation and increased stem cell populations
[45]. The binding of cognate ligands to the Notch receptor
is followed by proteolytic cleavage of Notch, releasing its
intracellular active domain. Notch translocates to the nu-
cleus and interacts with DNA-binding proteins such as
CSL, converting it from a transcriptional repressor to an
activator [67,68]. Notch also binds Mastermind-like 1
(MAML1) to further elevate CSL-regulated transcriptional
activation [69]. The Notch/CSL/MAML pathway targets
the HES and HERP families of basic helix-loop-helix
(bHLH) transcriptional repressors [70]. Conserved HES-
binding sites in turn, can be found in the promoter regions
of ROCK2 and MRCKα genes, the effectors of RhoA and
CDC42, respectively. Notch promotes the repressor func-
tion of HES1 leading to the downregulation of ROCK2
and MRCKα gene expression [45]. Furthermore, use of
DAPT increased the expression of ROCK1 and 2, support-
ing the idea that Notch1 normally controls these genes in
keratinocytes to prevent tumour progression [45]. The
transcript levels of Notch have been shown to be upregu-
lated in mouse embryos treated with trichostatin A, a po-
tent HDAC-inhibitor [71]. Therefore, there is evidence to
suggest that Notch1 not only negatively regulates ROCK1
at the promoter level but that HDAC inhibitors upregulate
Notch1 gene expression.
In HD matrix, we find that Notch1 but not p53 was
upregulated by MS-275 and the increase in Notch1 levels
was independent of CHX. When Notch1 activation was
blocked using a γ-secretase inhibitor, DAPT, or when
Notch1 levels were reduced by pooled siRNA transfec-
tion, the effect of MS-275 on ROCK1 activity was abro-
gated. The data suggest that MS-275 directly upregulates
Notch1, which in turn blocks ROCK1 expression perhaps
via repressor activities on the ROCK1 promoter [45].
Conclusion
This work shows that amoeboid tumour cells migrate in
stiff matrices by upregulating ROCK1 activity and cell
contractility via an epigenetically-derived, Notch1-
dependant mechanism (Figure 8). However, the require-
ment for ROCK1 is conditional upon the availability of
other mechanisms such as proteolysis-assisted migration.
Methods
Reagents
N- (2-aminophenyl)-4-[N- (pyridin-3-yl -methoxycarbonyl)
aminomethyl) benzamide (MS-275) was purchased fromEnzo Life Sciences, International (Plymouth Meeting, PA).
(R)-(+)-trans-4- (1-Aminoethyl)-N- (4-Pyridyl) cyclohexa-
necarboxamide dihydrochloride monohydrate (Y-27632),
N- [N- (3,5-Difluorophenacetyl)-L-alanyl)-S-phenylglycine
t-butyl ester (DAPT), and 3-[2-(3,5-Dimethyl-2-oxocyclo-
hexyl)-2-hydroxyethylglutarimide, actidione, naramycin A
(Cycloheximide), and Valproic acid were purchased from
Sigma (Sigma-Aldrich, Corp., St. Louis, Mo). GM6001 was
purchased from Calbiochem (Calbiochem, SanDiego, CA).
Mammary tissue accrual and histochemistry
Mammary tissue containing DCIS was surgically resected
in accordance with standard health care procedures and
with human research ethics committee (HREC) approvals
(USyd #09-2009/12168 and Peter MacCallum #08/21).
Human studies were performed in accordance with the eth-
ical standards laid down in the 1964 Declaration of Helsinki
and its later amendments. Patients have given informed
consent to participate in the study. Mammary tissue col-
lected from patients undergoing subcutaneous mastectomy
for breast carcinoma was sliced thickly (~1 cm thick) in the
superior-inferior axis, fixed in neutral buffered formalin and
subjected to specimen radiography. Areas containing HMT
or LMT were removed from the slice after registration with
a specimen mammogram of the slice, transferred into 9.0%
sucrose in 0.1 M phosphate buffer for 12 h and embedded
in OCT compound. Routine 5 μm thick sections were cut
with a Bright OTF cryostat at −30°C and fixed with absolute
acetone at −20°C for 10 min. Masson’s Trichrome or H&E
were used to stain these sections.
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Collagen content within HMT and LMT tissues was esti-
mated against picrosirius red collagen standards (up to
31.93 mg/cm3). HMT and LMT tissues, HD matrices and
samples with known collagen concentrations were stained
with 200 μl 1% (w/v) Sirius red (Sigma-Aldrich) in saturated
picric acid solution (Sigma-Aldrich) for 30 min. The sam-
ples were then washed in 0.02 M acetic acid followed by
10000 x g centrifugation for 1 min until all unbound stain
was removed. Collagen-bound stain was then extracted in
the presence of 0.5 M NaOH. Absorbance of the eluted
stain was read at 531 nm using a VictorX Multilabel plate
reader (PerkinElmer, Waltham, MA).
Electron microscopy
Samples were fixed in 2.5% glutaraldehyde followed by
1% Osmium tetroxide, dehydrated in a graded series of
ethanol and critical point dried. SEM images were taken
with the Zeiss Ultra field emission scanning electron mi-
croscopy (FESEM) (Carl Zeiss), using the SE2 or In Lens
detector, 2 kV and of a working distance of 4 mm.
Cell culture and transfection
Rat mammary adenocarcinoma cells, MTLn3, were
grown in Advanced Dulbecco’s modified Eagle’s medium
(Adv D-MEM), supplemented with 5% fetal bovine
serum, 1% GlutaMax and 1% antibiotic- antimycotic
(Invitrogen/Gibco, Carlsbad, CA), at 37°C and 5% CO2
incubator and subcultured at 80% confluency. Twenty-
four hours prior to transfection, 4 × 104 cells were
seeded on 12 well plates. Rat Notch-1 ON-TARGET plus
SMART Pool siRNA from Dharmacon (Thermo Fisher
Scientific, Lafayette, CO) and non-targeted scrambled
siRNA from Ambion (Ambion, Austin, TX) were trans-
fected using DharmFECT 1 transfection agent. Twenty-
four hours after transfection, cells were trypsinized and
grown on the high-density collagen matrices for 24 h and
then fresh medium was replaced with or without drugs.
Forty-eight hours after drug treatments, cells were harvested
and total RNA and protein were extracted for further analysis.
Preparation of collagen matrices and seeding cells
High-density collagen matrices were prepared by using
20 mg/cm3 concentrated collagen. Around 500 μl of
10 mg/cm3 acid-solubilised monomeric rat tail type I
collagen (BD Biosciences, San Jose, CA) was centrifuged
in a microcon-YM-30 column containing a 30 kDa
filter cartridge (Millipore, Billerica, MA) for 60 min.
Around 50–100 μl of concentrated collagen was added
to the 14 mm microwell of a glass-bottom culture dish
(MatTek Corporation, Ashland, MA). Collagen was
polymerised by NH4OH vapour and the matrices were
washed with 1X PBS and incubated in complete medium
overnight in a humidified, 37°C and 5% CO2 incubator.Low-density (LD) collagen matrices were made by ap-
propriate dilution of collagen followed by polymerisation
at 37°C incubator. The present model studies how
tumour cells enter high-density (HD) collagen matrices
that are similar in density to stromal matrices. MTLn3
cells (10 X 104) were seeded on top of control LD and
HD collagen matrices and were allowed to migrate for
24 h. The samples were then washed to remove non-
adherent cells, treated with drugs or vehicle for another
48 h (unless otherwise stated) and then prepared for im-
aging, total RNA extraction or protein extraction. At the
end of the 72 h in control untreated samples, 89% (n = 4
experiments) and 100% (n = 2 experiments) of total cells
in the matrices have invaded into LD and HD matrices,
respectively.
Light microscopy and cell invasion quantitation
Differential interference contrast (DIC) live cell imaging
was performed on an Olympus CellR Live-Cell Micro-
scope equipped with a 5% CO2 and 37°C enclosure
(Olympus). Images of Masson’s Trichrome were captured
using the Zeiss Axioskop 2 MAT Light Microscope (Carl
Zeiss, Goettingen, Germany).
For quantitation of migration depth, treated and con-
trol cells were washed in pre-warmed PBS and cells
were fixed in 4% paraformaldehyde for 20 min, followed
by washing, and permeabilisation in 0.1% Triton X-100
for 5 min. Cells were stained in with Alexa fluor 488
phalloidin (Invitrogen) for 15 min. Stained cells were
imaged by confocal and collagen by reflection micros-
copy using an Olympus FluoView FV1000 microscope
(Olympus, Tokyo, Japan). Reflection microscopy was
performed by scanning with either the 488 or 559 nm
laser line and detected by passing the reflected light
through the DM405/488/559/635 dichroic and captur-
ing within the bandwidth of 485–490 nm for the 488
scan or 555–560 nm for the 559 nm scan. Individual
stacks were projected along the z-axis and migration
depth was measured from the collagen surface to the
ventral cell surface using ImageJ. Cells were sampled
randomly for imaging and for the analyses.
Extraction of total RNA
Total RNA was extracted from treated and control cells
to study the gene expression pattern. Culture medium
was aspirated and cells were washed in pre-warmed PBS.
Collagen matrices were transferred into 1.5 ml of eppen-
dorf tubes and 1 ml of TRIzolW reagent (Invitrogen) was
added to each gel and homogenized by pipetting up and
down. After homogenisation, the tubes were incubated
for 5 min at room temperature and 0.2 ml of chloroform
was added to each tube and shook for 15 s. The mixture
was incubated for another 5 min at room temperature
and spun down at 13,000 rpm at 4°C for 15 min. The
Raviraj et al. BMC Cell Biology 2012, 13:12 Page 14 of 17
http://www.biomedcentral.com/1471-2121/13/12upper aqueous layer was transferred into a new tube and
same volume of 70% ethanol was added into the tubes.
It was mixed thoroughly and mixture was transferred
into the RNeasy Mini spin column (Qiagen, Hilden,
Germany) and remaining steps were followed accord-
ing to manufacturer’s protocol.
Reverse transcription and real-time quantitative PCR
(RT-qPCR)
Reverse transcription was performed using SuperScript III
First-Strand synthesis system (Invitrogen) according to the
manufacturer’s protocol. We have quantified expression
levels of some of the genes, which are responsible for cell
invasion and proliferation using fluorescence detection
method (primer list attached on Additional file 5: Table S1);
10 μl of Brilliant SYBR master mix (Stratagene, La Jolla,
CA) or Express SYBRW GreenER (Invitrogen), 0.25 μM pri-
mers and 1 μl of cDNA were used in 20 μl of total reaction.
The relative mRNA level was calculated by the 2-ΔΔCT
method. GAPDH was used as an internal control.
RT-qPCR experiments were performed in Rotagene 6000
from Corbett Research. Initial denaturation was at 95°C for
10 min. The cycling conditions afterwards were as follows:
95°C for 10 s, annealing dependent on the primer
temperature, and elongation at 72°C for 20–30 s. Melting
curve analysis was performed between 72°C and 98°C. Each
sample was assayed in triplicate, each experiment had at
least 2 biological replicates, and each experiment was
performed at least 3 times.
Protein extraction and western blot analysis
Collagen matrices containing migratory cells were
washed in PBS and transferred to 24 well plates. Matri-
ces were digested by 0.5 mg/ml of collagenase (Sigma-
Aldrich) in Kreb’s Ringer buffer supplemented with
50 mM CaCl2 at 37°C for 30 min. Cells were pelleted at
2000 rpm, were washed in ice-cold PBS. RIPA buffer
(Sigma-Aldrich) that contain freshly added protease in-
hibitor cocktail (Sigma-Aldrich), was added to each pel-
let, mixed thoroughly and incubated for 1 h in the ice.
Cell lysate was centrifuged at 13,000 rpm for 15 min
at 4°C. Concentration of protein in the supernatant was
determined using Bio-Rad protein assay dye reagent
(Bio-Rad Laboratories, Hercules, CA). Twenty micro-
gram of protein was solubilised in SDS-sample buffer
at 95°C for 5 min, and separated by SDS-PAGE using
8–10% resolving gels. Proteins were electroblotted onto
immunoblot PVDF membrane (Millipore). After transfer,
membranes were blocked in 5% skim milk/TBST for 1 h
and the membrane washed three times in TBST. The
membranes were incubated overnight at 4°C in 1% skim
milk/TBST containing primary antibodies that were spe-
cific for ROCK1 (H-85) (1:500) or Notch1 (1:1000) from
Santa Cruz (Santa Cruz Biotechnology, SantaCruz, CA).After washing with TBST, membranes were incubated
with 1% skim milk/TBST containing secondary antibody
conjugated to horseradish peroxidase (GE Healthcare Bio-
Sciences Corp, Piscataway, NJ) for 1 h. The blot signal
was visualized by using enhanced chemiluminescence
hyperfilm (GE Healthcare). Blots were then stripped at
room temperature for 30 min in Restore plus western blot
stripping buffer (Thermo Fisher Scientific) and reprobed
with mouse anti-α-tubulin (1:2500) monoclonal antibody.ROCK activity assay and immunoblotting
ROCK activity was measured using ROCK activity
immunoblot kit from Cell Biolabs Inc (Cell Biolabs Inc.
San Diego, CA). The reaction was carried out with slight
modification of manufacturer’s protocol; 65 μl of Kinase/
ATP/Substrate solution was prepared by adding 3 μl of
10 mM ATP and 3 μl of ROCK substrate (recombinant
MYPT1) to 59 μl of freshly prepared 1X Kinase buffer
and then 10 μl of 1X Kinase/ATP/Substrate solution and
10 μg of whole cell lysate protein from treated or un-
treated cells were used for the kinase reaction. The kin-
ase reaction was initiated by incubating tubes at 30°C for
1 h with gentle agitation and stopped by adding SDS-
sample buffer. Protein mixture was boiled at 95°C for
5 min. Protein was separated in 12% resolving gel.
Rabbit anti-phospho-MYPT1 (Thr696) primary antibody
(1:1000) was used to detect the phosphorylated MYPT1
substrate.Rheology
Rheological analyses for measuring the viscoelastic prop-
erties of collagen gels were performed using the Physica
MCR 301 (Anton-Paar GmbH, Austria) and a cone plate
of 50 mm in diameter. Collagen gels (50 mm in diameter
and 1 mm in thickness) were loaded onto the rheometer
lower plate. The upper cone plate was slowly lowered
onto the collagen gel until full contact was achieved.
Frequency sweep oscillations from 0.01 to 30 Hz were
performed and the storage modulus (G’) and loss modu-
lus (G”) were recorded. For the frequency sweep oscilla-
tion measurements, 1% maximal strain and shear rates
from 0.000626 to 1.87 1/s was used.Morphometric measurements and statistics
Cell morphology was analysed using ImageJ. The outline
for each cell was traced and parameter measurements were
obtained for Circularity and Aspect Ratio. The data were
transferred to Microsoft Excel for analysis and statistical
evaluations. Data were expressed as Mean ± SD. Analyses
were performed by Student t-test or one- way ANOVA fol-
lowed by post-hoc Tukey’s test. P values less than or equal
to 0.05 were considered statistically significant.
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Additional file 1: Movie S1. Tumour cell migration in HD matrix by live
cell imaging. Live cell imaging from differential interference contrast (DIC)
microscopy showing a tumour cell (MTLn3) moving through HD matrix.
Frame rate = 15 s/frame. Bar = 10 μm.
Additional file 2: Figure S1. Effects of blebbistatin on cell migration in
HD matrix. Blebbistatin (6.25 uM) was added 5 h after seeding MTLn3
cells onto HD matrix and the cells were allowed to migrate for a further
24 h prior to fixation, staining with phalloidin actin, imaging and
measurements of invasion depth. Graph illustrates the degree of
migration in microns of vehicle- and blebbistatin-treated cells.
Additional file 3: Figure S2. HDAC inhibitor, VPA suppresses the ROCK1
expression. MTLn3 breast cancer cells were allowed to invade into HD
matrix for 24 h, were treated with VPA, DAPT, and combined treatments
for 48 h. The cells were harvested for mRNA expression analysis. Q-PCR
results showed that VPA alone decreased ROCK1 transcript level (40%)
compared with control. Conversely, blocking of Notch-1 increased the
ROCK1 mRNA level (75%) compared with control. Combination of VPA
with DAPT, brought back the transcript level of ROCK1 similar to control.
VPA increased the expression of Notch-1 transcript (150%) compared
with control. DNA gel pictures represent the Q-PCR results. Relative
expression was calculated using DDCt method and GAPDH used as
internal control. Bars indicate standard error from two biological
replicates and the experiments were repeated at least twice. 1-way
ANOVA followed by post-hoc Tukey’s test indicating significant difference
at * p < 0.05 and** p < 0.01.
Additional file 4: Figure S3. CHX increases p53 expression in HD
matrix. MTLn3 breast cancer cells were allowed to invade into HD
matrices for 24 h before treatment with 1 μM and 3 μM MS-275, 10 μg/
ml of cycloheximide (CHX) and both CHX and MS-275 and cells were
grown for further 24 h. Treatment of MS-275 at both concentrations did
not affect the expression of p53 transcript in HD matrix. However,
treatment of CHX increases the p53 expression. Bar indicates standard
error from two biological samples and experiments were performed two
times. 1-way ANOVA followed by post-hoc Tukey’s test indicating
significant difference at either * p < 0.05 or ** p < 0.01.
Additional file 5: Table S1. Primers used for real time RT-PCR reactions.
The primers were designed using Primer3 software. All the primer pairs
spanned an exon-exon junction to prevent genomic DNA amplifications.
The specificity of all primer sequences were tested with Basic Local
Alignment Search Tool (BLAST;http://www.ncbi.nlm.nih.gov/blast/Blast.
cgi). The annealing temperature of the primers was ~ 60oC and size of
the PCR amplicons were range from 200–250 bp.
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